NewsRoom Articles - Page 2 of 245

WednesdayJul 22, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany

The company has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”) supporting the proposed development strategy for its lead BiTAC(R)-TCE program. The regulatory feedback provides early guidance on the company’s biological rationale, safety assessments, and non-clinical development plan, for its novel therapeutic platform. VERAXA believes the advice helps reduce development uncertainty by providing greater clarity before advancing toward clinical studies. The company’s lead BiTAC(R)-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting. VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (“ADCs”) and other engineered…

TuesdayJul 21, 2026 11:15 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Supporting Lucid-MS’s phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital. The company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. Neurological disorders affect hundreds of millions of people worldwide, and for many of those patients, existing treatments fall far short. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company, is working to change…

TuesdayJul 21, 2026 10:00 am

Study Finds No Evidence That Mobile Phones Can Cause Brain Cancer

For a long time, many people have claimed that using a mobile phone can cause brain cancer. These fears were so widespread that the World Health Organization commissioned teams to conduct 13 reviews aimed at establishing whether electromagnetic waves, such as those that enable mobile phones to work, had any health effects. The reviews were commissioned back in 2019. The World Health Organization hasn’t released its own findings of those reviews. However, a study that was published last week provides an analysis of the WHO-funded reviews. The researchers show that the available data doesn’t provide any evidence to suggest that electromagnetic waves released by mobile phones cause brain cancer or cancer of the neck…

TuesdayJul 21, 2026 9:45 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Hits Key Study Milestone as Early MS Imaging Data Shows Promising Signal

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Multiple sclerosis is one of the most common neurological diseases affecting young adults worldwide. Study is evaluating technique that allows researchers to tell the difference between nerve damage that may still be reversible and damage that is permanent. Quantum BioPharma reports two key developments: patient enrollment in the pilot study has reached its halfway mark and preliminary imaging data is encouraging. A key imaging study examining a novel approach to tracking multiple sclerosis (“MS”) has reached its halfway point in patient enrollment, with early results showing a…

MondayJul 20, 2026 9:45 am

Earth Science Tech Inc. (ETST) Continues to Optimize Operational and Financial Frameworks to Maintain Its Singular Position of Strength

Earth Science Tech, a strategic holding company in the healthcare, pharmacy, and telemedicine sector, is distinct from other OTC listed companies based on its record of strong results, hard real estate assets, vertical integration, and robust corporate structure The company has reported year-over-year growth in revenue and gross profits since fiscal year 2024, progress attributable to careful strategic and complementary investments and acquisitions, which have not added debt to its balance sheet Its acquisition of Avenvi created a subsidiary that develops, manages, and finances real estate and owns property that houses ETST’s Texas pharmacy Investopedia lists the lack of reliable…

FridayJul 17, 2026 10:00 am

Study Links Gut Microbial Metabolites to Enhanced Cancer Immunotherapy Sensitivity

Scientists have been racing to establish why some patients respond to cancer immunotherapy while others do not. A recent study has linked metabolites produced by certain bacteria in the gut to improved responses to cancer immunotherapy in patients. The study, whose findings were published in the journal Cell Reports Medicine, was conducted by a large team led by researchers at the University of Nebraska and Cedars-Sinai, alongside collaborators based at other academic institutions. Ramer-Tait from the University of Nebraska led the research effort. Previous research has variously linked gut microbiota to improved responses to cancer immunotherapy. However, no study had pinpointed a specific microbe or microbial metabolite linked to immunotherapy response improvements…

ThursdayJul 16, 2026 10:00 am

Initiatives to Erase Medical Debt Gain Traction Across the US

According to KFF research conducted in 2022, about 100 million individuals in the U.S. are saddled with medical debt. This debt often makes it nearly impossible for them to afford other necessities of life, including additional medical care. As lawmakers on Capitol Hill drag their feet on enacting definitive remedies to the escalating healthcare costs, state governments and philanthropists are taking action to wipe medical debt away. Undue Medical Debt is a nonprofit organization that is focused on mobilizing donations and using the funds it gets to wipe away the crippling medical debt that low-income earners in the U.S. face. The nonprofit has come up with a model through which…

WednesdayJul 15, 2026 9:00 am

Earth Science Tech Inc. (ETST) Leveraging Technology and Strategic Positioning to Advance the Industry and Stamp Its Market Position

Earth Science Tech has positioned itself within the rapidly evolving telehealth industry, through its investments into subsidiaries such as DOConsultations LLC and Las Villas Health Care Inc. The company is capitalizing on the surging demand and clinical effectiveness of peptide therapies, an industry expected to hit $249 billion by 2033. ETST’s success has been built on its proprietary tech and IT infrastructure, a significant competitive edge, and continues to push innovative tech development and expand vertical integration. Earth Science Tech (OTC: ETST), a strategic holding company building value by acquiring and actively managing operating businesses in pharmaceuticals, telemedicine, healthcare services,…

TuesdayJul 14, 2026 10:00 am

Expert Highlights Growing Evidence That Links Respiratory Infections to Cardiovascular Diseases

Not many people know that respiratory infections have been strongly linked to cardiovascular disease events, and this knowledge gap is leading to missed opportunities to use readily accessible vaccines to limit the severity and challenges arising from cardiovascular disease. Professor Colin Russell, based at the School of Medicine at Amsterdam University, explains why it is important to understand the role that respiratory infections play in cardiovascular disease. He points out that fragmented data on immunization coverage is a leading barrier that prevents vaccination against respiratory infections from making a bigger contribution in the fight against cardiovascular disease. Prof. Russell points…

TuesdayJul 14, 2026 9:45 am

Why VERAXA Biotech AG (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D

Artificial intelligence is becoming an increasingly important tool for drug discovery, with major pharmaceutical companies expanding AI collaborations across oncology and immunology. VERAXA Biotech has partnered with AI-focused contract research organization Ardigen to strengthen discovery efforts for its BiTAC(R) cancer therapy platform. The collaboration aims to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates while reducing development risks. VERAXA's Boolean "AND-gated" BiTAC(R) technology presents a use case that may be particularly well suited for AI-assisted target selection and therapeutic design. AI analysis of historical clinical and preclinical datasets could help identify promising targets that were previously abandoned because…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions

Study Finds No Evidence That Mobile Phones Can Cause Brain Cancer

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Hits Key Study Milestone as Early MS Imaging Data Shows Promising Signal

Earth Science Tech Inc. (ETST) Continues to Optimize Operational and Financial Frameworks to Maintain Its Singular Position of Strength

Study Links Gut Microbial Metabolites to Enhanced Cancer Immunotherapy Sensitivity

Initiatives to Erase Medical Debt Gain Traction Across the US

Earth Science Tech Inc. (ETST) Leveraging Technology and Strategic Positioning to Advance the Industry and Stamp Its Market Position

Expert Highlights Growing Evidence That Links Respiratory Infections to Cardiovascular Diseases

Why VERAXA Biotech AG (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search